Beyond NSCLC, amino acid transporter-targeted 211At radiopharmaceuticals have demonstrated potent and selective antitumor efficacy across multiple malignancies, highlighting their broad translational promise. This evidence concerns the gene SLC38A7 and non-small cell lung carcinoma.